These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15688619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
    Cuevas C, Francesch A.
    Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
    [Abstract] [Full Text] [Related]

  • 7. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M, Jimeno J.
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [Abstract] [Full Text] [Related]

  • 8. Marine natural products as anticancer drugs.
    Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH.
    Mol Cancer Ther; 2005 Feb; 4(2):333-42. PubMed ID: 15713904
    [Abstract] [Full Text] [Related]

  • 9. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
    Martínez N, Sánchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernández I, Navarrete M, Jimeno J, Piris MA.
    Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C, Jerusalem G.
    Rev Med Liege; 2011 May; 66(7-8):452-5. PubMed ID: 21942081
    [Abstract] [Full Text] [Related]

  • 13. Progress in the clinical development of new marine-derived anticancer compounds.
    Jimeno J, López-Martín JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K.
    Anticancer Drugs; 2004 Apr; 15(4):321-9. PubMed ID: 15057135
    [Abstract] [Full Text] [Related]

  • 14. Ecteinascidin-743.
    Held-Warmkessel J.
    Clin J Oncol Nurs; 2003 Apr; 7(3):313-9. PubMed ID: 12793338
    [Abstract] [Full Text] [Related]

  • 15. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
    Tognon G, Frapolli R, Zaffaroni M, Erba E, Zucchetti M, Faircloth GT, D'Incalci M.
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):89-90. PubMed ID: 14586558
    [No Abstract] [Full Text] [Related]

  • 16. Unique features of trabectedin mechanism of action.
    Larsen AK, Galmarini CM, D'Incalci M.
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sea squirt assaults sarcomas.
    Burton A.
    Lancet Oncol; 2002 Nov; 3(11):648. PubMed ID: 12424055
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
    Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, Von Hoff DD.
    Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.